Equities research analysts forecast that Phreesia (NYSE:PHR) will post $29.32 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Phreesia’s earnings, with estimates ranging from $28.53 million to $30.80 million. The firm is expected to report its next quarterly earnings report after the market closes on Monday, September 9th.

According to Zacks, analysts expect that Phreesia will report full-year sales of $118.52 million for the current financial year, with estimates ranging from $118.24 million to $118.90 million. For the next financial year, analysts expect that the company will report sales of $141.87 million, with estimates ranging from $141.61 million to $142.31 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Phreesia.

A number of equities analysts have recently commented on PHR shares. Wells Fargo & Co started coverage on shares of Phreesia in a research note on Monday, August 12th. They set an “outperform” rating and a $23.00 price objective for the company. Piper Jaffray Companies set a $33.00 price objective on shares of Phreesia and gave the stock a “buy” rating in a research note on Tuesday. Chardan Capital started coverage on shares of Phreesia in a research note on Tuesday, July 23rd. They set a “buy” rating and a $33.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of Phreesia in a research note on Tuesday, August 13th. They set an “overweight” rating and a $33.00 price objective for the company. Finally, William Blair started coverage on shares of Phreesia in a research note on Monday, August 12th. They set an “outperform” rating for the company. Five research analysts have rated the stock with a buy rating, Phreesia presently has a consensus rating of “Buy” and an average price target of $30.50.

In related news, major shareholder Ii L.P. Chv sold 335,767 shares of the firm’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $18.00, for a total value of $6,043,806.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott Perricelli sold 743,388 shares of the firm’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $18.00, for a total transaction of $13,380,984.00. The disclosure for this sale can be found here.

Shares of Phreesia stock traded up $0.58 during trading hours on Monday, reaching $26.19. 211,379 shares of the company’s stock were exchanged, compared to its average volume of 278,212. The business’s 50 day moving average is $26.67. Phreesia has a fifty-two week low of $22.05 and a fifty-two week high of $29.38.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

Read More: What are no-load funds?

Get a free copy of the Zacks research report on Phreesia (PHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.